…the ear. The genes are encased in a viral vector, which is essentially a harmless virus that transports the genes to hair cells in the inner ear. Hair cells are…
…condition, LCA; and Eyevensys will soon start a first trial in uveitis with the first gene therapy that does not use viral vectors. Images via GeK / Shutterstock; NightstaRx …
…In the open-label trial, the University of Oxford spin-off enrolled 23 patients with advanced castration-resistant prostate cancer. The patients received the company’s viral vector vaccine in combination with the approved…
…oxidative stress. The DNA of the two distinct isoforms (RdCVF and RdCVFL) of the NXNL1 gene are supplied via an Adeno-associated virus (AAV), the viral vector of choice for retinal…
…Sputnik V. The vaccine — made using adenoviral vectors like AstraZeneca’s vaccine — was given emergency authorization in more than 70 countries, including the EU member states Hungary and Slovakia….
…viruses modified to selectively target tumor antigens and adenoviral vectors for the delivery of cancer antigens. Comment: The company is getting ready to compete against the big players in immuno-oncology…
…to cure himself, but four days after he was injected with an adenoviral vector to test the treatment’s safety, Gelsinger suffered a massive immune response to the virus that caused…
…from viral vector-delivered gene transductions or genetic engineering that CAR-based cell therapies require. This approach allows for the development of off-the-shelf allogeneic cell therapies that are more broadly accessible for…
…Therapies’ platform is the option to manufacture the lentiviral vectors needed to genetically engineer CAR-T cells within the same platform. As a result, CAR-T developers can rely on a single…
…and PD, with the potential to develop further programs.” Under the collaboration, Coave Therapeutics will use its AAV-Ligand Conjugate (ALIGATER) platform to design, develop and manufacture coAAV viral vectors carrying…
…indication, adding to their current target multiple myeloma. The company’s technology targets the immunosuppressive microenvironment that surrounds a tumor, which protects cancer cells from attack. A lentiviral vector delivers a…
…immune cells present, which can attack viral vectors carrying the therapy. Ophthalmological gene therapies have been the focus of numerous recent funding rounds, including small rounds closed by Amarna Therapeutics…